Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Aug 6;56(2):2000206.
doi: 10.1183/13993003.00206-2020. Print 2020 Aug.

Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis

Nicola Adderley  1 , Christopher J Humphreys  2 , Hayley Barnes  3   4 , Brett Ley  4 , Zahra A Premji  5 , Kerri A Johannson  6   7
Affiliations
Free article
Meta-Analysis

Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis

Nicola Adderley et al. Eur Respir J. .
Free article

Abstract

Background: The role of bronchoalveolar lavage fluid (BALF) lymphocyte percentage in diagnosing chronic hypersensitivity pneumonitis (CHP) is unclear. We conducted a systematic review and meta-analysis of bronchoalveolar lavage (BAL) lymphocyte percentage in the diagnosis of CHP.

Methods: We searched Medline, Embase and the Cochrane Library from inception to August 2019. Individual patient data were obtained to test performance characteristics of BAL lymphocyte percentage at different thresholds. Random-effects models were used for pooled estimates, with comparisons made between CHP and non-CHP interstitial lung diseases (ILDs).

Results: Fifty-three studies were included in the systematic review and 42 in the meta-analysis. The pooled estimate for BAL lymphocyte percentage was 42.8% (95% CI 37.7-47.8, I2=95.3%) in CHP, 10.0% (95% CI 6.9-13.1, I2=91.2%) in idiopathic pulmonary fibrosis (IPF), 23.1% (95% CI 3.0-43.2, I2=85.2%) in non-IPF idiopathic interstitial pneumonia (IIP), 23.4% (95% CI 11.0-35.9, I2=45.7%) in connective-tissue disease associated ILD (CTD-ILD) and 31.2% (95% CI 17.6-44.8, I2=95.2%) in sarcoidosis. Results differed between CHP and IPF (p<0.0001), non-IPF IIP (p=0.0309) or CTD-ILD (p=0.0824), but not between CHP and sarcoidosis (p=0.0966). Using individual patient data from eight studies, a lymphocyte percentage threshold of >20% provided a sensitivity of 68.1% and a specificity of 64.8% for CHP. Higher thresholds provided lower sensitivity with higher specificity. Older age and ever having smoked were associated with lower lymphocyte percentage in CHP.

Conclusions: BAL lymphocyte percentage is higher in CHP compared to IPF and other IIPs, with higher thresholds providing improved specificity at the cost of sensitivity. However, the parent studies are at risk of incorporation bias and prospective studies should evaluate the additive discriminate value of BAL lymphocyte percentage to accurately diagnose CHP.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: N. Adderley has nothing to disclose. Conflict of interest: C.J. Humphreys has nothing to disclose. Conflict of interest: H. Barnes has nothing to disclose. Conflict of interest: B. Ley has nothing to disclose. Conflict of interest: Z.A. Premji has nothing to disclose. Conflict of interest: K.A. Johannson reports personal fees for advisory board work, consultancy, lectures and travel to meetings from Boehringer Ingelheim, personal fees for advisory board work and lectures from Hoffman La Roche Ltd, personal fees for advisory board work and consultancy from Theravance and Blade Therapeutics, grants from the Chest Foundation, the University of Calgary School of Medicine, the Pulmonary Fibrosis Society of Calgary and UCB Biopharma SPRL, outside the submitted work.

Comment in

LinkOut - more resources